Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy

Inclusion Criteria

• •Advanced (unresectable or metastatic) biopsy-proven pancreatic Neuroendocrine tumor (NET)
• •Confirmed low-grade or intermediate-grade neuroendocrine carcinoma
• •Objective disease progression by Response Evaluation Criteria in Solid tumors (RECIST) criteria while receiving cytotoxic chemotherapy or at any time after receiving an adequate course of cytotoxic chemotherapy (i.e., at least 3 consecutive cycles or months of treatment with the same cytotoxic drug or regimen)
• •Presence of at least one measurable disease using RECIST criteria at screening (computer tomography \[CT\] or Magnetic resonance imaging \[MRI\])
• •Adequate bone marrow, liver and kidney function
• •WHO Performance Status 0-2.
• •Receiving treatment (at least 3 consecutive months) with Octreotide Depot.
• •In addition to documentation of progressive disease on or after chemotherapy, patients in stratum 2 must have documented objective progression of disease while receiving Octreotide Depot.